<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="iso-abbrev">Antimicrob. Agents Chemother</journal-id><journal-id journal-id-type="hwp">aac</journal-id><journal-id journal-id-type="pmc">aac</journal-id><journal-id journal-id-type="publisher-id">AAC</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology</publisher-name><publisher-loc>1752 N St., N.W., Washington, DC</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5923093</article-id><article-id pub-id-type="pmid">29483126</article-id><article-id pub-id-type="publisher-id">02360-17</article-id><article-id pub-id-type="doi">10.1128/AAC.02360-17</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Therapeutics</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>The Clarithromycin Susceptibility Genotype Affects the Treatment Outcome of Patients with Mycobacterium abscessus Lung Disease </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="running-head"><named-content content-type="genus-species">M. abscessus</named-content> Genotype, Lung Disease, and Treatment</alt-title><alt-title alt-title-type="short-authors">Guo et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Guo</surname><given-names>Qi</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Chu</surname><given-names>Haiqing</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="aff" rid="aff5"><sup>e</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ye</surname><given-names>Meiping</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Zhemin</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Bing</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Shiyi</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Fangyou</given-names></name><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><aff id="aff1"><label>a</label>Tongji University School of Medicine, Shanghai, China</aff><aff id="aff2"><label>b</label>Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China</aff><aff id="aff3"><label>c</label>State Key Laboratory of Microbial Metabolism, and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China</aff><aff id="aff4"><label>d</label>Department of Clinical Laboratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China</aff><aff id="aff5"><label>e</label>Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China</aff></contrib-group><author-notes><corresp id="cor1">Address correspondence to Haiqing Chu, <email>chu_haiqing@126.com</email>, or Meiping Ye, <email>yemeiping1988@163.com</email>.</corresp><fn fn-type="other"><p><text><SENT sid="1" pm="."><plain>Citation Guo Q, Chu H, Ye M, Zhang Z, Li B, Yang S, Ma W, Yu F. 2018. </plain></SENT>
<SENT sid="3" pm="."><plain>The clarithromycin susceptibility genotype affects the treatment outcome of patients with Mycobacterium abscessus lung disease. </plain></SENT>
<SENT sid="4" pm="."><plain>Antimicrob Agents Chemother 62:e02360-17. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/AAC.02360-17">https://doi.org/10.1128/AAC.02360-17</ext-link>. </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="epreprint"><day>26</day><month>2</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>26</day><month>4</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>4</month><year>2018</year></pub-date><volume>62</volume><issue>5</issue><elocation-id>e02360-17</elocation-id><history><date date-type="received"><day>16</day><month>11</month><year>2017</year></date><date date-type="rev-request"><day>20</day><month>1</month><year>2018</year></date><date date-type="accepted"><day>13</day><month>2</month><year>2018</year></date></history><permissions><copyright-statement>Copyright © 2018 Guo et al.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Guo et al.</copyright-holder><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="zac005187122001.pdf"/><abstract><title><text><SENT sid="5" pm="."><plain>ABSTRACT </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="6" pm="."><plain>Mycobacterium abscessus accounts for a large proportion of lung disease cases caused by rapidly growing mycobacteria. </plain></SENT>
<SENT sid="7" pm="."><plain>The association between clarithromycin sensitivity and treatment outcome is clear. </plain></SENT>
<SENT sid="8" pm="."><plain>However, M. abscessus culture and antibiotic susceptibility testing are time-consuming. </plain></SENT>
<SENT sid="9" pm="."><plain>Clarithromycin susceptibility genotyping offers an alternate, rapid approach to predicting the efficacy of clarithromycin-based antibiotic therapy. M. abscessus lung disease patients were divided into two groups based upon the clarithromycin susceptibility genotype of the organism isolated. </plain></SENT>
<SENT sid="10" pm="."><plain>A retrospective analysis was conducted to compare the clinical features, microbiological characteristics, and treatment outcomes of the two groups. </plain></SENT>
<SENT sid="11" pm="."><plain>Several other potential predictors of the response to treatment were also assessed. </plain></SENT>
<SENT sid="12" pm="."><plain>Sixty-nine patients were enrolled in the clarithromycin-resistant genotype group, which included 5 infected with rrl 2058-2059 mutants and 64 infected with erm(41)T28-type M. abscessus; 31 were in the clarithromycin-sensitive group, i.e., 6 and 25 patients infected with genotypes erm(41)C28 and erm(41) M type, respectively. </plain></SENT>
<SENT sid="13" pm="."><plain>The results showed that lung disease patients infected with clarithromycin-sensitive and -resistant M. abscessus genotypes differed significantly in clarithromycin-based combination treatment outcomes. </plain></SENT>
<SENT sid="14" pm="."><plain>Patients infected with the clarithromycin-sensitive genotype exhibited higher initial and final sputum-negative conversion and radiological improvement rates and better therapeutic outcomes. </plain></SENT>
<SENT sid="15" pm="."><plain>Multivariate analysis demonstrated that genotyping was a reliable and, more importantly, rapid means of predicting the efficacy of clarithromycin-based antibiotic treatment for M. abscessus lung disease. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><title>KEYWORDS</title><kwd><named-content content-type="genus-species">Mycobacterium abscessus</named-content></kwd><kwd>clarithromycin</kwd><kwd>genotype</kwd><kwd>lung disease</kwd><kwd>treatment outcome</kwd></kwd-group></SecTag><funding-group><award-group id="award1"><funding-source id="gs1"><institution-wrap><institution>Medical Guide Program of Shanghai Science and Technology Committee</institution></institution-wrap></funding-source><award-id rid="gs1">14411962900</award-id><principal-award-recipient><name><surname>Chu</surname><given-names>Haiqing</given-names></name></principal-award-recipient></award-group><award-group id="award2"><funding-source id="gs2"><institution-wrap><institution>Key Project of Shanghai Municipal Health and Family Planning Commission</institution></institution-wrap></funding-source><award-id rid="gs2">201540367</award-id><principal-award-recipient><name><surname>Chu</surname><given-names>Haiqing</given-names></name></principal-award-recipient></award-group><award-group id="award3"><funding-source id="gs3"><institution-wrap><institution>Youth Project of Shanghai Municipal Health and Family Planning Commission</institution></institution-wrap></funding-source><award-id rid="gs3">20164Y0230</award-id><principal-award-recipient><name><surname>Li</surname><given-names>Bing</given-names></name></principal-award-recipient></award-group><award-group id="award4"><funding-source id="gs4"><institution-wrap><institution>New Frontier Technology Joint Project of Municipal Hospital, Shanghai Shenkang Hospital Develoment Center</institution></institution-wrap></funding-source><award-id rid="gs4">SHDC12017113</award-id><principal-award-recipient><name><surname>Chu</surname><given-names>Haiqing</given-names></name></principal-award-recipient></award-group><award-group id="award5"><funding-source id="gs5"><institution-wrap><institution>National Natural Science Foundation of China (NSFC)</institution><institution-id>https://doi.org/10.13039/501100001809</institution-id></institution-wrap></funding-source><award-id rid="gs5">81672063</award-id><principal-award-recipient><name><surname>Chu</surname><given-names>Haiqing</given-names></name></principal-award-recipient></award-group></funding-group><counts><count count="1" count-type="supplementary-material"/><fig-count count="2"/><table-count count="5"/><equation-count count="0"/><ref-count count="31"/><page-count count="11"/><word-count count="6732"/></counts><custom-meta-group><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><SecTag type="INTRO"><sec sec-type="intro" id="sec1"><title><text><SENT sid="16" pm="."><plain>INTRODUCTION </plain></SENT>
</text></title><p><text><SENT sid="17" pm="."><plain>The incidence of infections by nontuberculosis mycobacteria (NTM) has increased significantly in recent years (1–3). </plain></SENT>
<SENT sid="18" pm="."><plain>Of all NTM infections, treatment of Mycobacterium abscessus infections is the most challenging (4, 5). M. abscessus accounts for 65 to 80% of the cases of lung disease caused by rapidly growing mycobacteria and has emerged as an important pathogen for patients with bronchiectasis, chronic obstructive pulmonary disease, and cystic fibrosis (6–11). </plain></SENT>
</text></p><p><text><SENT sid="19" pm="."><plain>M. abscessus is among the most antibiotic-resistant pathogens known (12). </plain></SENT>
<SENT sid="20" pm="."><plain>Although some antibiotics, such as amikacin, cefoxitin, and imipenem, are effective, only clarithromycin (CLA) exhibits convincing evidence of clinical efficacy for treatment of M. abscessus lung disease (8). </plain></SENT>
<SENT sid="21" pm="."><plain>Currently, CLA is the only effective antibiotic administered orally and, therefore, recommended as the core agent for treatment of M. abscessus infections (8). </plain></SENT>
</text></p><p><text><SENT sid="22" pm="."><plain>Genotypic variations influence the sensitivity of M. abscessus to CLA. </plain></SENT>
<SENT sid="23" pm="."><plain>Two genotypes confer CLA resistance: a point mutation (A to C or A to G) in the 2058-2059 locus of the 23S rRNA (rrl) gene confers acquired resistance (13). </plain></SENT>
<SENT sid="24" pm="."><plain>An intact erm(41) gene, which exhibits a T/C polymorphism at the 28th nucleotide, confers inducible resistance when the 28th nucleotide is thymidine [erm(41)T28] (14, 15). </plain></SENT>
<SENT sid="25" pm="."><plain>Alternatively, CLA sensitivity is conferred when cytidine is the 28th nucleotide in intact erm(41), i.e., genotype erm(41)C28 (15). </plain></SENT>
<SENT sid="26" pm="."><plain>Deletion of erm(41) nucleotides 64 and 65, or deletion of nucleotides 159 to 432, also results in the loss of erm(41) gene function (M type) and a gain in CLA sensitivity (14, 16). </plain></SENT>
</text></p><p><text><SENT sid="27" pm="."><plain>M. abscessus can be divided into M. abscessus subsp. abscessus and M. abscessus subsp. massiliense based upon the integrity or absence of the erm(41) gene. </plain></SENT>
<SENT sid="28" pm="."><plain>Korean and Japanese researchers first reported that M. abscessus subsp. abscessus and M. abscessus subsp. massiliense exhibited disparate clinical and microbiological characteristics (17, 18). </plain></SENT>
<SENT sid="29" pm="."><plain>Retrospective analysis and a prospective study conducted in 2017 confirmed these results and suggested that patients infected with a CLA-sensitive [erm(41)C28] genotype had a prognostic advantage (19, 20). </plain></SENT>
<SENT sid="30" pm="."><plain>Therefore, differences in the A and M subtypes may be due largely to genotypic differences that affect CLA sensitivity (21–23). </plain></SENT>
<SENT sid="31" pm="."><plain>Here, we report the results of a retrospective analysis undertaken to determine the relationship between genotype, CLA sensitivity, and the outcome of CLA-based treatment of M. abscessus lung disease. </plain></SENT>
</text></p></sec></SecTag><SecTag type="RESULTS"><sec sec-type="results" id="sec2"><title><text><SENT sid="32" pm="."><plain>RESULTS </plain></SENT>
</text></title><sec id="sec2-1"><title><text><SENT sid="33" pm="."><plain>Patient characteristics. </plain></SENT>
</text></title><p><text><SENT sid="34" pm="."><plain>One hundred M. abscessus lung disease patients who conformed to our recruitment criteria were enrolled and divided into CLA-resistant and -sensitive genotype groups according to the rrl and erm(41) sequevar. </plain></SENT>
<SENT sid="35" pm="."><plain>Sixty-nine (69%) patients were enrolled in the CLA-resistant genotype group, which included 5 (7.2%) rrl 2058-2059 mutant- and 64 (92.8%) erm(41)T28-type-infected patients; 31 (31%) belonged to the CLA-sensitive genotype group, which included 6 (19.4%) erm(41)C28- and 25 (80.6%) erm(41) M-type-infected patients. </plain></SENT>
<SENT sid="36" pm="."><plain>No significant differences were found in the ages and genders of the two groups (Table 1). </plain></SENT>
<SENT sid="37" pm="."><plain>The proportion of patients with hemoptysis was higher in the CLA-resistant genotype group than the CLA-sensitive genotype group (22/69 versus 4/31; P = 0.045). </plain></SENT>
<SENT sid="38" pm="."><plain>Furthermore, a significantly greater incidence of cavity-like manifestations occurred in computed tomography (CT) scans of patients infected with isolates with the CLA-resistant genotype than in patients infected with isolates with the CLA-sensitive genotype (50/69 versus 8/31; P &lt; 0.001). </plain></SENT>
<SENT sid="39" pm="."><plain>CT scans of the CLA-sensitive-group patients, on the other hand, displayed a higher incidence of a tree-in-bud pattern (14/31 versus 16/69; P = 0.027). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T1" orientation="portrait" position="float"><label>TABLE 1</label><caption><p><text><SENT sid="40" pm="."><plain>Baseline characteristics of patients infected with M. abscessus belonging to CLA-resistant and -sensitive genotypes </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr valign="bottom"><th rowspan="2" align="left" colspan="1"><text><SENT sid="41" pm="."><plain>Characteristica </plain></SENT>
</text></th><th colspan="2" align="left" rowspan="1"><text><SENT sid="42" pm="."><plain>Valueb </plain></SENT>
</text></th><th rowspan="2" align="left" colspan="1"><text><SENT sid="43" pm="."><plain>P value </plain></SENT>
</text></th></tr><tr valign="bottom"><th align="left" rowspan="1" colspan="1"><text><SENT sid="44" pm="."><plain>CLA-resistant group (n = 69) </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="45" pm="."><plain>CLA-sensitive group (n = 31) </plain></SENT>
</text></th></tr></thead><tbody><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="46" pm="."><plain>Median age (IQR) (yr) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="47" pm="."><plain>58 (44–66) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="48" pm="."><plain>56 (32–64) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="49" pm="."><plain>0.562 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="50" pm="."><plain>Males </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="51" pm="."><plain>26 (37.7) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="52" pm="."><plain>17 (54.8) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="53" pm="."><plain>0.107 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="54" pm="."><plain>BMI (mean ± SD) (kg/m2) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="55" pm="."><plain>19.93 ± 0.37 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="56" pm="."><plain>19.69 ± 0.57 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="57" pm="."><plain>0.729 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="58" pm="."><plain>Underlying disease </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="59" pm="."><plain>    Prior tuberculosisc </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="60" pm="."><plain>29 (42.0) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="61" pm="."><plain>16 (51.6) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="62" pm="."><plain>0.373 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="63" pm="."><plain>    COPD </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="64" pm="."><plain>1 (1.4) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="65" pm="."><plain>2 (6.5) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="66" pm="."><plain>0.226 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="67" pm="."><plain>    Hypertension </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="68" pm="."><plain>11 (15.9) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="69" pm="."><plain>3 (9.7) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="70" pm="."><plain>0.601 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="71" pm="."><plain>    Diabetes </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="72" pm="."><plain>2 (2.9) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="73" pm="."><plain>4 (12.9) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="74" pm="."><plain>0.135 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="75" pm="."><plain>    CHD </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="76" pm="."><plain>4 (5.8) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="77" pm="."><plain>0 (0) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="78" pm="."><plain>0.414 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="79" pm="."><plain>    Malignancy </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="80" pm="."><plain>3 (4.3) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="81" pm="."><plain>0 (0) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="82" pm="."><plain>0.550 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="83" pm="."><plain>History of surgery </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="84" pm="."><plain>3 (4.3) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="85" pm="."><plain>1 (3.2) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="86" pm="."><plain>1 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="87" pm="."><plain>Symptoms </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="88" pm="."><plain>    Cough </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="89" pm="."><plain>55 (79.7) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="90" pm="."><plain>25 (80.6) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="91" pm="."><plain>0.914 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="92" pm="."><plain>    Sputum </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="93" pm="."><plain>69 (100.0) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="94" pm="."><plain>31 (100.0) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="95" pm="."><plain>1 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="96" pm="."><plain>    Fever </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="97" pm="."><plain>15 (21.7) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="98" pm="."><plain>4 (12.9) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="99" pm="."><plain>0.298 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="100" pm="."><plain>    Hemoptysis </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="101" pm="."><plain>22 (31.9) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="102" pm="."><plain>4 (12.9) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="103" pm="."><plain>0.045 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="104" pm="."><plain>Radiographic features </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="105" pm="."><plain>    Extent </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="106" pm="."><plain>0.404 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="107" pm="."><plain>        Bilateral involvement </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="108" pm="."><plain>58 (84.0) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="109" pm="."><plain>28 (90.3) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="110" pm="."><plain>        Unilateral involvement </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="111" pm="."><plain>11 (15.9) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="112" pm="."><plain>3 (9.7) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="113" pm="."><plain>    Median no. of lobes (IQR) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="114" pm="."><plain>4 (3–6) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="115" pm="."><plain>4 (2–6) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="116" pm="."><plain>0.419 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="117" pm="."><plain>    Disease pattern </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="118" pm="."><plain>        Bronchiectasis </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="119" pm="."><plain>66 (95.7) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="120" pm="."><plain>29 (93.4) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="121" pm="."><plain>0.655 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="122" pm="."><plain>        Cavity </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="123" pm="."><plain>50 (72.5) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="124" pm="."><plain>8 (25.8) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="125" pm="."><plain>&lt;0.001 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="126" pm="."><plain>        Nodules (diam &lt; 1 cm) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="127" pm="."><plain>38 (55.0) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="128" pm="."><plain>19 (61.3) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="129" pm="."><plain>0.561 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="130" pm="."><plain>        Nodules (diam &gt; 1 cm) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="131" pm="."><plain>39 (56.5) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="132" pm="."><plain>16 (51.6) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="133" pm="."><plain>0.648 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="134" pm="."><plain>        Tree-in-bud pattern </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="135" pm="."><plain>16 (23.2) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="136" pm="."><plain>14 (45.2) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="137" pm="."><plain>0.027 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="138" pm="."><plain>Initial AFB smear positivity </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="139" pm="."><plain>28 (40.6) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="140" pm="."><plain>10 (32.3) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="141" pm="."><plain>0.428 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="142" pm="."><plain>Initial morphotype </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="143" pm="."><plain>0.770 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="144" pm="."><plain>    Rough </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="145" pm="."><plain>40 (58.0) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="146" pm="."><plain>17 (54.8) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="147" pm="."><plain>    Smooth </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="148" pm="."><plain>29 (42.0) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="149" pm="."><plain>14 (45.2) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn fn-type="abbr" id="T1F1"><label>a</label><p><text><SENT sid="150" pm="."><plain>COPD, chronic obstructive pulmonary disease; CHD, coronary heart disease; AFB, acid-fast bacilli; IQR, interquartile range. </plain></SENT>
</text></p></fn><fn fn-type="other" id="T1F2"><label>b</label><p><text><SENT sid="151" pm="."><plain>Data are the numbers (%) of patients found in the CLA-resistant and -sensitive genotype groups unless otherwise indicated. </plain></SENT>
</text></p></fn><fn fn-type="other" id="T1F3"><label>c</label><p><text><SENT sid="152" pm="."><plain>Patients treated for tuberculosis prior to the diagnosis of M. abscessus lung disease. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag></sec><sec id="sec2-2"><title><text><SENT sid="153" pm="."><plain>Colony morphology. </plain></SENT>
</text></title><p><text><SENT sid="154" pm="."><plain>M. abscessus isolates manifest two distinct colony morphotypes: smooth and rough. </plain></SENT>
<SENT sid="155" pm="."><plain>The colony morphology of the isolates associated with both CLA susceptibility groups did not differ significantly (Table 1). </plain></SENT>
<SENT sid="156" pm="."><plain>Patients infected with M. abscessus characterized by a rough-type colony exhibited a higher incidence of cavities in CT images (P = 0.043) (Table 2). </plain></SENT>
<SENT sid="157" pm="."><plain>The colony morphotype did not exert a significant effect on any of the other parameters assessed. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T2" orientation="portrait" position="float"><label>TABLE 2</label><caption><p><text><SENT sid="158" pm="."><plain>Relationship between morphotype, results of initial CT scan, and treatment outcome </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr valign="bottom"><th rowspan="2" align="left" colspan="1"><text><SENT sid="159" pm="."><plain>Parameter </plain></SENT>
</text></th><th colspan="2" align="left" rowspan="1"><text><SENT sid="160" pm="."><plain>No. </plain></SENT>
<SENT sid="161" pm="."><plain>(%) of patientsa </plain></SENT>
</text></th><th rowspan="2" align="left" colspan="1"><text><SENT sid="162" pm="."><plain>P value </plain></SENT>
</text></th></tr><tr valign="bottom"><th align="left" rowspan="1" colspan="1"><text><SENT sid="163" pm="."><plain>Rough n = 57 </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="164" pm="."><plain>Smooth n = 43 </plain></SENT>
</text></th></tr></thead><tbody><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="165" pm="."><plain>Radiographic features </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="166" pm="."><plain>    Bronchiectasis </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="167" pm="."><plain>56 (98.2) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="168" pm="."><plain>39 (90.7) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="169" pm="."><plain>0.211 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="170" pm="."><plain>    Tree-in-bud pattern </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="171" pm="."><plain>18 (31.6) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="172" pm="."><plain>12 (27.9) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="173" pm="."><plain>0.692 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="174" pm="."><plain>    Cavity </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="175" pm="."><plain>38 (66.7) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="176" pm="."><plain>20 (46.5) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="177" pm="."><plain>0.043 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="178" pm="."><plain>Radiological improvement </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="179" pm="."><plain>26 (45.6) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="180" pm="."><plain>21 (48.8) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="181" pm="."><plain>0.749 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="182" pm="."><plain>Sputum conversion to negativity </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="183" pm="."><plain>21 (36.8) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="184" pm="."><plain>19 (44.2) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="185" pm="."><plain>0.458 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="186" pm="."><plain>Treatment effectiveness </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="187" pm="."><plain>31 (54.4) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="188" pm="."><plain>25 (58.1) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="189" pm="."><plain>0.708 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn fn-type="other" id="T2F1"><label>a</label><p><text><SENT sid="190" pm="."><plain>Number (percentage) of patients infected with isolates that give rise to rough and smooth colony types versus the disease parameter listed. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag></sec><sec id="sec2-3"><title><text><SENT sid="191" pm="."><plain>Comparison of antibiotic sensitivity. </plain></SENT>
</text></title><p><text><SENT sid="192" pm="."><plain>The sensitivity of all the M. abscessus isolates to 10 antibiotics tested is shown in Table 3 and Table S1 in the supplemental material. </plain></SENT>
<SENT sid="193" pm="."><plain>The five rrl 2058-2059 mutant isolates exhibited acquired resistance to CLA, i.e., they were resistant on day 3 of exposure and prior to induction. </plain></SENT>
<SENT sid="194" pm="."><plain>Twenty-seven of the 64 erm(41)T28 isolates also exhibited acquired resistance; 36 isolates were induced by 14 days exposure to CLA; and one isolate showed abnormal CLA sensitivity despite expressing an erm(41)T28 gene, albeit with a wild-type rrl gene. </plain></SENT>
<SENT sid="195" pm="."><plain>In sharp contrast, no CLA resistance was observed within the CLA-sensitive genotype group. </plain></SENT>
<SENT sid="196" pm="."><plain>Notably, although most isolates in the CLA-resistant genotype group were insensitive to CLA, only one isolate was insensitive to amikacin treatment. </plain></SENT>
<SENT sid="197" pm="."><plain>A considerable number of isolates in both the CLA-sensitive and CLA-resistant genotype groups were sensitive to linezolid. </plain></SENT>
<SENT sid="198" pm="."><plain>A large number of isolates in both groups were resistant to moxifloxacin, doxycycline, imipenem, and tobramycin; no significant difference in resistance to these antibiotics was found between groups. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T3" orientation="portrait" position="float"><label>TABLE 3</label><caption><p><text><SENT sid="199" pm="."><plain>Antibiotic resistance of all M. abscessus isolatesa </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr valign="bottom"><th rowspan="2" align="left" colspan="1"><text><SENT sid="200" pm="."><plain>Isolate group (n) </plain></SENT>
</text></th><th rowspan="2" align="left" colspan="1"><text><SENT sid="201" pm="."><plain>Antibiotic </plain></SENT>
</text></th><th colspan="12" align="left" rowspan="1"><text><SENT sid="202" pm="."><plain>No. of isolates/MIC (mg/ml) of: </plain></SENT>
</text></th><th rowspan="2" align="left" colspan="1"><text><SENT sid="203" pm="."><plain>No. </plain></SENT>
<SENT sid="204" pm="."><plain>(%) resistant isolatesb </plain></SENT>
</text></th></tr><tr valign="bottom"><th align="left" rowspan="1" colspan="1"><text><SENT sid="205" pm="."><plain>0.06 </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="206" pm="."><plain>0.125 </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="207" pm="."><plain>0.25 </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="208" pm="."><plain>0.5 </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="209" pm="."><plain>1 </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="210" pm="."><plain>2 </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="211" pm="."><plain>4 </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="212" pm="."><plain>8 </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="213" pm="."><plain>16 </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="214" pm="."><plain>32 </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="215" pm="."><plain>64 </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="216" pm="."><plain>128 </plain></SENT>
</text></th></tr></thead><tbody><tr valign="top"><td rowspan="11" colspan="1"><text><SENT sid="217" pm="."><plain>Resistant (69) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="218" pm="."><plain>Clarithromycin before induction </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="219" pm="."><plain>7 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="220" pm="."><plain>11 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="221" pm="."><plain>13 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="222" pm="."><plain>10 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="223" pm="."><plain>9 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="224" pm="."><plain>19 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="225" pm="."><plain>28 (40.6) </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="226" pm="."><plain>Clarithromycin after induction </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="227" pm="."><plain>1 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="228" pm="."><plain>68 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="229" pm="."><plain>68 (98.6) </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="230" pm="."><plain>Amikacin </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="231" pm="."><plain>2 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="232" pm="."><plain>13 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="233" pm="."><plain>35 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="234" pm="."><plain>10 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="235" pm="."><plain>8 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="236" pm="."><plain>1 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="237" pm="."><plain>1 (1.4) </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="238" pm="."><plain>Linezolid </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="239" pm="."><plain>1 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="240" pm="."><plain>3 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="241" pm="."><plain>2 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="242" pm="."><plain>10 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="243" pm="."><plain>20 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="244" pm="."><plain>33 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="245" pm="."><plain>33 (47.8) </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="246" pm="."><plain>Moxifloxacin </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="247" pm="."><plain>1 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="248" pm="."><plain>3 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="249" pm="."><plain>65 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="250" pm="."><plain>68 (98.6) </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="251" pm="."><plain>Doxycycline </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="252" pm="."><plain>1 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="253" pm="."><plain>68 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="254" pm="."><plain>68 (98.6) </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="255" pm="."><plain>Imipenem </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="256" pm="."><plain>3 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="257" pm="."><plain>14 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="258" pm="."><plain>52 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="259" pm="."><plain>66 (95.7) </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="260" pm="."><plain>Tobramycin </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="261" pm="."><plain>9 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="262" pm="."><plain>22 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="263" pm="."><plain>38 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="264" pm="."><plain>60 (87.0) </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="265" pm="."><plain>Cefoxitin </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="266" pm="."><plain>3 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="267" pm="."><plain>23 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="268" pm="."><plain>43 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="269" pm="."><plain>43 (62.3) </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="270" pm="."><plain>Sulfonamides </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="271" pm="."><plain>2 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="272" pm="."><plain>7 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="273" pm="."><plain>22 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="274" pm="."><plain>22 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="275" pm="."><plain>16 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="276" pm="."><plain>38 (55.1) </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="277" pm="."><plain>Tigecycline </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="278" pm="."><plain>4 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="279" pm="."><plain>10 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="280" pm="."><plain>30 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="281" pm="."><plain>16 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="282" pm="."><plain>9 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="283" pm="."><plain>ND </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="11" colspan="1"><text><SENT sid="284" pm="."><plain>Sensitive (31) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="285" pm="."><plain>Clarithromycin before induction </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="286" pm="."><plain>2 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="287" pm="."><plain>9 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="288" pm="."><plain>4 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="289" pm="."><plain>8 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="290" pm="."><plain>3 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="291" pm="."><plain>3 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="292" pm="."><plain>3 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="293" pm="."><plain>6 (19.4) </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="294" pm="."><plain>Clarithromycin after induction </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="295" pm="."><plain>7 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="296" pm="."><plain>4 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="297" pm="."><plain>7 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="298" pm="."><plain>4 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="299" pm="."><plain>1 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="300" pm="."><plain>4 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="301" pm="."><plain>4 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="302" pm="."><plain>8 (25.8) </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="303" pm="."><plain>Amikacin </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="304" pm="."><plain>2 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="305" pm="."><plain>3 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="306" pm="."><plain>15 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="307" pm="."><plain>9 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="308" pm="."><plain>1 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="309" pm="."><plain>1 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="310" pm="."><plain>1 (3.2) </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="311" pm="."><plain>Linezolid </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="312" pm="."><plain>1 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="313" pm="."><plain>7 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="314" pm="."><plain>10 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="315" pm="."><plain>13 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="316" pm="."><plain>13 (42.0) </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="317" pm="."><plain>Moxifloxacin </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="318" pm="."><plain>1 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="319" pm="."><plain>2 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="320" pm="."><plain>28 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="321" pm="."><plain>30 (96.8) </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="322" pm="."><plain>Doxycycline </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="323" pm="."><plain>1 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="324" pm="."><plain>30 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="325" pm="."><plain>31 (100) </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="326" pm="."><plain>Imipenem </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="327" pm="."><plain>1 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="328" pm="."><plain>4 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="329" pm="."><plain>26 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="330" pm="."><plain>30 (96.8) </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="331" pm="."><plain>Tobramycin </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="332" pm="."><plain>1 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="333" pm="."><plain>9 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="334" pm="."><plain>21 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="335" pm="."><plain>30 (96.8) </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="336" pm="."><plain>Cefoxitin </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="337" pm="."><plain>2 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="338" pm="."><plain>7 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="339" pm="."><plain>22 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="340" pm="."><plain>22 (71.0) </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="341" pm="."><plain>Sulfonamides </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="342" pm="."><plain>1 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="343" pm="."><plain>5 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="344" pm="."><plain>7 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="345" pm="."><plain>10 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="346" pm="."><plain>8 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="347" pm="."><plain>18 (58.1) </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="348" pm="."><plain>Tigecycline </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="349" pm="."><plain>2 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="350" pm="."><plain>6 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="351" pm="."><plain>10 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="352" pm="."><plain>7 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="353" pm="."><plain>6 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="354" pm="."><plain>ND </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn fn-type="other" id="T3F1"><label>a</label><p><text><SENT sid="355" pm="."><plain>The erm(41) sequevar-dependent resistance of 100 M. abscessus isolates to the antibiotics indicated was determined by the microdilution method. </plain></SENT>
<SENT sid="356" pm="."><plain>The incubation time was 3 days (before) and 14 days (after) induction for CLA and 3 days for the other antibiotics listed. </plain></SENT>
</text></p></fn><fn fn-type="other" id="T3F2"><label>b</label><p><text><SENT sid="357" pm="."><plain>Resistant isolates were distinguished according to the breakpoint provided by NCCLS document M24-A2. </plain></SENT>
<SENT sid="358" pm="."><plain>ND, no data. </plain></SENT>
<SENT sid="359" pm="."><plain>Tigecycline has no recommended breakpoint. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag></sec><sec id="sec2-4"><title><text><SENT sid="360" pm="."><plain>Combination antibiotic treatment and treatment response. </plain></SENT>
</text></title><p><text><SENT sid="361" pm="."><plain>All patients enrolled in the study were treated with a standard combination of antibiotics based upon CLA. </plain></SENT>
<SENT sid="362" pm="."><plain>Patients infected with the CLA-sensitive genotype group isolates were significantly more likely to demonstrate initial sputum conversion (Fig. 1 and Table 4) (P = 0.011). </plain></SENT>
<SENT sid="363" pm="."><plain>Times to initial sputum conversion also differed significantly between the CLA-sensitive and CLA-resistant genotype groups (P = 004). </plain></SENT>
<SENT sid="364" pm="."><plain>Sputum relapse after initial conversion to negative occurred in both groups and did not differ significantly. </plain></SENT>
<SENT sid="365" pm="."><plain>The proportion of patients whose sputa converted and remained culture-negative during the follow-up period was significantly greater in the CLA-sensitive than in the CLA-resistant genotype group (61.3% versus 30.4%, respectively; P = 0.013). </plain></SENT>
<SENT sid="366" pm="."><plain>Radiographic improvement rates were significantly higher in patients infected with the CLA-sensitive genotype group isolates than in patients infected with the CLA-resistant genotype group (P = 0.006). </plain></SENT>
<SENT sid="367" pm="."><plain>The effective treatment response evaluated by radiology and microbiology was also significantly greater for the CLA-sensitive genotype group than for the CLA-resistant genotype group (P &lt; 0.001). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F1" orientation="portrait" position="float"><label>FIG 1</label><caption><p><text><SENT sid="368" pm="."><plain>Comparison of initial sputum smear/culture conversion between patients infected with the CLA-resistant [2058-2059 rrl mutant or rrl wild type/erm(41)T28] and -sensitive [rrl wild type/erm(41)C28 or rrl wild type/erm(41) M type] genotype groups. </plain></SENT>
<SENT sid="369" pm="."><plain>Patients infected with the resistant group isolates showed a significantly longer initial sputum medium conversion time: 12 months versus 7 months for the sensitive group (P = 0.004). </plain></SENT>
</text></p></caption><graphic xlink:href="zac0051871220001"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="T4" orientation="portrait" position="float"><label>TABLE 4</label><caption><p><text><SENT sid="370" pm="."><plain>Treatment outcomes for CLA-resistant and -sensitive genotype groups </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr valign="bottom"><th rowspan="2" align="left" colspan="1"><text><SENT sid="371" pm="."><plain>Parameter </plain></SENT>
</text></th><th colspan="2" align="left" rowspan="1"><text><SENT sid="372" pm="."><plain>Valuea </plain></SENT>
</text></th><th rowspan="2" align="left" colspan="1"><text><SENT sid="373" pm="."><plain>P value </plain></SENT>
</text></th></tr><tr valign="bottom"><th align="left" rowspan="1" colspan="1"><text><SENT sid="374" pm="."><plain>Resistant group (n = 69) </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="375" pm="."><plain>Sensitive group (n = 31) </plain></SENT>
</text></th></tr></thead><tbody><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="376" pm="."><plain>Median duration of treatment [mo (IQR)] </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="377" pm="."><plain>18 (9–30) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="378" pm="."><plain>15 (9–22) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="379" pm="."><plain>0.260 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="380" pm="."><plain>Sputum result </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="381" pm="."><plain>0.013 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="382" pm="."><plain>    Conversion to stable negative </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="383" pm="."><plain>21 (30.4) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="384" pm="."><plain>19 (61.3) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="385" pm="."><plain>    Failure to convert </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="386" pm="."><plain>39 (56.5) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="387" pm="."><plain>9 (29.0) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="388" pm="."><plain>    Relapse after conversion to negative </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="389" pm="."><plain>9 (13.0) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="390" pm="."><plain>3 (9.7) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="391" pm="."><plain>Initial smear/culture conversion </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="392" pm="."><plain>    No. of patients who initially converted </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="393" pm="."><plain>30 (43.5) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="394" pm="."><plain>22 (71.0) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="395" pm="."><plain>0.011 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="396" pm="."><plain>    Median time to initial conversion [mo (IQR)] </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="397" pm="."><plain>12 (6–23) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="398" pm="."><plain>7 (5–11) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="399" pm="."><plain>0.004 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="400" pm="."><plain>Radiological result </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="401" pm="."><plain>    Improved </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="402" pm="."><plain>25 (36.2) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="403" pm="."><plain>22 (71.0) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="404" pm="."><plain>0.006 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="405" pm="."><plain>    No change </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="406" pm="."><plain>24 (34.8) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="407" pm="."><plain>5 (16.1) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="408" pm="."><plain>    Progressed </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="409" pm="."><plain>20 (30.0) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="410" pm="."><plain>4 (12.9) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="411" pm="."><plain>Final treatment response </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="412" pm="."><plain>    Effective </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="413" pm="."><plain>30 (43.5) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="414" pm="."><plain>26 (83.9) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="415" pm="."><plain>&lt;0.001 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="416" pm="."><plain>    Failure </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="417" pm="."><plain>39 (56.5) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="418" pm="."><plain>5 (16.1) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn fn-type="other" id="T4F1"><label>a</label><p><text><SENT sid="419" pm="."><plain>The data are the number and (percentage) of patients in each group unless otherwise indicated. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="420" pm="."><plain>In multivariate analysis, the genotype was a reliable predictor of the response of M. abscessus lung disease to treatment (odds ratio [OR] = 0.185; 95% confidence interval [CI], 0.059 to 0.579; P = 0.004) (Table 5). </plain></SENT>
<SENT sid="421" pm="."><plain>All other characteristics, i.e., age, sex, body mass index (BMI), colony morphology, and CT imaging, were nonpredictors. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T5" orientation="portrait" position="float"><label>TABLE 5</label><caption><p><text><SENT sid="422" pm="."><plain>Univariate and multivariate analyses of factors affecting combination antibiotic treatment </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr valign="bottom"><th align="left" rowspan="1" colspan="1"><text><SENT sid="423" pm="."><plain>Variable </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="424" pm="."><plain>Unadjusted OR (95% CI) </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="425" pm="."><plain>P value </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="426" pm="."><plain>Adjusted OR (95% CI) </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="427" pm="."><plain>P value </plain></SENT>
</text></th></tr></thead><tbody><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="428" pm="."><plain>Age (yr) </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="429" pm="."><plain>    &gt;58 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="430" pm="."><plain>0.72 (0.33–1.60) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="431" pm="."><plain>0.421 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="432" pm="."><plain>    &lt;58 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="433" pm="."><plain>1 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="434" pm="."><plain>Sex </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="435" pm="."><plain>    Male </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="436" pm="."><plain>1.93 (0.86–4.36) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="437" pm="."><plain>0.113 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="438" pm="."><plain>    Female </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="439" pm="."><plain>1 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="440" pm="."><plain>BMI </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="441" pm="."><plain>    &gt;20.0 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="442" pm="."><plain>1.10 (0.48–2.35) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="443" pm="."><plain>0.884 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="444" pm="."><plain>    &lt;20.0 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="445" pm="."><plain>1 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="446" pm="."><plain>Resistance of isolates </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="447" pm="."><plain>    Resistant </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="448" pm="."><plain>0.15 (0.051–0.431) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="449" pm="."><plain>&lt;0.001 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="450" pm="."><plain>0.185 (0.059–0.579) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="451" pm="."><plain>0.004 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="452" pm="."><plain>    Sensitive </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="453" pm="."><plain>1 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="454" pm="."><plain>1 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="455" pm="."><plain>Initial morphotype </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="456" pm="."><plain>    Rough </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="457" pm="."><plain>0.86 (0.39–1.91) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="458" pm="."><plain>0.708 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="459" pm="."><plain>    Smooth </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="460" pm="."><plain>1 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="461" pm="."><plain>Positive AFB smear </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="462" pm="."><plain>    Yes </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="463" pm="."><plain>1.13 (0.50–2.56) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="464" pm="."><plain>0.765 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="465" pm="."><plain>    No </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="466" pm="."><plain>1 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="467" pm="."><plain>Bronchiectasis </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="468" pm="."><plain>    Yes </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="469" pm="."><plain>1.98 (0.32–12.37) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="470" pm="."><plain>0.467 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="471" pm="."><plain>    No </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="472" pm="."><plain>1 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="473" pm="."><plain>Tree-in-bud pattern </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="474" pm="."><plain>    Yes </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="475" pm="."><plain>2.91 (1.14–7.42) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="476" pm="."><plain>0.025 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="477" pm="."><plain>2.217 (0.810–6.068) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="478" pm="."><plain>0.121 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="479" pm="."><plain>    No </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="480" pm="."><plain>1 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="481" pm="."><plain>1 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="482" pm="."><plain>Cavity </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="483" pm="."><plain>    Yes </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="484" pm="."><plain>0.39 (0.17–0.90) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="485" pm="."><plain>0.027 </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="486" pm="."><plain>0.776 (0.298–2.022) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="487" pm="."><plain>0.603 </plain></SENT>
</text></td></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="488" pm="."><plain>    No </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="489" pm="."><plain>1 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"><text><SENT sid="490" pm="."><plain>1 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="491" pm="."><plain>Completed the initial 4 wk of treatment </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="492" pm="."><plain>    Yes </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="493" pm="."><plain>1.38 (0.55–3.45) </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="494" pm="."><plain>0.498 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td rowspan="1" colspan="1"><text><SENT sid="495" pm="."><plain>    No </plain></SENT>
</text></td><td rowspan="1" colspan="1"><text><SENT sid="496" pm="."><plain>1 </plain></SENT>
</text></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table></table-wrap></SecTag></sec></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="discussion" id="sec3"><title><text><SENT sid="497" pm="."><plain>DISCUSSION </plain></SENT>
</text></title><p><text><SENT sid="498" pm="."><plain>The study reported here was the first undertaken to explore and correlate the differences in treatment outcomes of M. abscessus lung disease patients with the CLA susceptibility genotype of clinical isolates. </plain></SENT>
<SENT sid="499" pm="."><plain>We found that the treatment results for patients infected with isolates with the CLA-sensitive M. abscessus genotype were far superior to the results for patients infected with isolates with the CLA-resistant genotype evaluated in terms of sputum conversion rate, duration of initial sputum conversion, radiological improvement, and efficacy. </plain></SENT>
<SENT sid="500" pm="."><plain>Treatment outcome, however, was independent of all other factors examined, which included BMI, colony morphology, and radiological images. </plain></SENT>
</text></p><p><text><SENT sid="501" pm="."><plain>In 2006, the M. abscessus complex was first divided into M. abscessus subsp. abscessus and M. abscessus subsp. massiliense based upon differences in the rpoB gene (24). </plain></SENT>
<SENT sid="502" pm="."><plain>In 2011, Bastian and coworkers reported that variations in the erm(41) genotype influenced the sensitivity of these subtypes to CLA in vitro (15). </plain></SENT>
<SENT sid="503" pm="."><plain>The clinical characteristics and treatment outcomes of patients infected with M. abscessus subsp. abscessus and M. abscessus subsp. massiliense differed in subsequent studies (17–20). </plain></SENT>
<SENT sid="504" pm="."><plain>Patients infected with M. abscessus subsp. massiliense usually responded better to treatment due, in part, to the CLA sensitivity of the organism. </plain></SENT>
<SENT sid="505" pm="."><plain>Several genotypes are associated with CLA sensitivity and -resistance: rrl mutant/wild type, erm(41)T28, erm(41)C28, and erm(41) M type. </plain></SENT>
<SENT sid="506" pm="."><plain>In the study described here, clinical isolates were grouped into these genotypes rather than M. abscessus subsp. abscessus and M. abscessus subsp. massiliense, and the responses of patients to standard, CLA-based treatment were assessed and compared. </plain></SENT>
<SENT sid="507" pm="."><plain>The response of the CLA-sensitive genotype group was significantly superior to that of the CLA-resistant genotype group judged in terms of the sputum conversion rate, radiological improvement, duration of initial sputum conversion results, and treatment efficacy. </plain></SENT>
<SENT sid="508" pm="."><plain>While lung disease patients infected with M. abscessus subsp. abscessus [erm(41)C28 genotype] isolates may exhibit a better response to combination CLA treatment, the response of patients infected with M. abscessus subsp. massiliense isolates expressing the 2058-2059 rrl mutation was often much worse. </plain></SENT>
<SENT sid="509" pm="."><plain>As such, CLA susceptibility genotyping is more accurate than subtyping as an approach to predicting the treatment outcomes of patients with M. abscessus lung disease (46.4% versus 42.9% true-positive rates, respectively). </plain></SENT>
</text></p><p><text><SENT sid="510" pm="."><plain>The effect of BMI on the treatment outcomes of patients with NTM lung disease was demonstrated in several studies (25, 26). </plain></SENT>
<SENT sid="511" pm="."><plain>A recent retrospective study suggested that, in addition to CLA sensitivity, BMI was a factor that affected the success of M. abscessus lung disease treatment (20). </plain></SENT>
<SENT sid="512" pm="."><plain>This suggestion, however, was not confirmed by the present study. </plain></SENT>
<SENT sid="513" pm="."><plain>The overall BMIs of M. abscessus lung disease patients enrolled in our study were low; moreover, multivariate analysis failed to support its value in predicting an effective treatment outcome. </plain></SENT>
<SENT sid="514" pm="."><plain>This finding is consistent with results reported by other investigators (19). </plain></SENT>
<SENT sid="515" pm="."><plain>Similarly, predictions concerning the outcome of antibiotic therapy based upon symptoms or CT imaging are unrealistic. </plain></SENT>
<SENT sid="516" pm="."><plain>While hemoptysis and cavity-like manifestations were more common among the patients infected with CLA-resistant genotype M. abscessus, these factors failed to predict the prognosis upon multivariate analysis. </plain></SENT>
</text></p><p><text><SENT sid="517" pm="."><plain>Patients infected with M. abscessus characterized by a rough-type colony exhibited a high incidence of cavities in CT images. </plain></SENT>
<SENT sid="518" pm="."><plain>This finding is consistent with the conclusion that rough-type strains usually exhibit higher virulence and pathogenicity. </plain></SENT>
<SENT sid="519" pm="."><plain>Unlike previous studies (19), however, we found that the initial colony morphology failed to correlate with the final radiologic improvement rate or treatment efficacy (Table 2). </plain></SENT>
<SENT sid="520" pm="."><plain>Jonsson and coworkers reported a significant increase in the number of rough colonies during the course of infection and the occurrence of smooth-to-rough colony conversion (27). </plain></SENT>
<SENT sid="521" pm="."><plain>Thus, we speculate that colony morphology is associated only with pathogenicity and the pathogenesis of infection and is not a reliable predictor of treatment efficacy. </plain></SENT>
</text></p><p><text><SENT sid="522" pm="."><plain>The study described here has several limitations. </plain></SENT>
<SENT sid="523" pm="."><plain>First, only a relative small number of isolates exhibited the rrl mutation and erm(41)C28 genotypes; consequently, their characteristics may not be representative. </plain></SENT>
<SENT sid="524" pm="."><plain>Solidifying their characteristics will require the enrollment of more patients infected with isolates exhibiting the rrl mutant and erm(41)C28 genotypes in future studies. </plain></SENT>
<SENT sid="525" pm="."><plain>Second, a minority of patients relapsed following initially successful treatment (see Table S2 in the supplemental material). </plain></SENT>
<SENT sid="526" pm="."><plain>Conceivably, these relapses were due to subsequent infection by a different M. abscessus strain or genotype. </plain></SENT>
<SENT sid="527" pm="."><plain>In the absence of dynamic follow-up, our study failed to determine whether recurrence occurred due to reinfection by a different M. abscessus strain. </plain></SENT>
</text></p><p><text><SENT sid="528" pm="."><plain>In conclusion, there was a significant difference in treatment outcomes for patients infected with CLA-resistant and -sensitive M. abscessus genotype isolates. </plain></SENT>
<SENT sid="529" pm="."><plain>The CLA-sensitive genotype group was significantly superior in sputum conversion rate, initial sputum conversion time, radiological improvement, and treatment efficacy. </plain></SENT>
<SENT sid="530" pm="."><plain>Accurate genotyping is an important factor in predicting the efficacy of combination therapy with CLA-based antibiotics. </plain></SENT>
<SENT sid="531" pm="."><plain>Rapid genotyping should help clinicians optimize therapeutic strategies, especially in cases of critically ill patients who cannot wait weeks for culture and susceptibility testing. </plain></SENT>
<SENT sid="532" pm="."><plain>Genotyping would also be effective as a diagnostic approach in areas where facilities for mycobacterial culture and susceptibility testing are unavailable. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="materials|methods" id="sec4"><title><text><SENT sid="533" pm="."><plain>MATERIALS AND METHODS </plain></SENT>
</text></title><sec id="sec4-1"><title><text><SENT sid="534" pm="."><plain>Study population. </plain></SENT>
</text></title><p><text><SENT sid="535" pm="."><plain>A retrospective review of the medical records of all patients with M. abscessus lung disease was conducted between January 2012 and December 2015 at the Shanghai Pulmonary Hospital. </plain></SENT>
<SENT sid="536" pm="."><plain>Patient inclusion criteria were as follows: (i) age, &gt;16 years; (ii) underwent initial diagnosis and treatment at the Shanghai Pulmonary Hospital in accordance with the 2007 American Thoracic Society/Infectious Disease Society of America (ATS/IDSA) guidelines; (iii) received oral CLA-based combination treatment; (iv) follow-up period lasted more than 6 months. </plain></SENT>
<SENT sid="537" pm="."><plain>The exclusion criteria were as follows: (i) age, &lt;16 years; (ii) history of NTM lung disease; (iii) lack of critical visit data (e.g., regular sputum culture or CT examination), failure to follow up, or death from non-M. abscessus lung disease-related causes; (iv) treatment did not include oral CLA; (v) history of long-term macrolide drug treatment; (vi) diagnosed with active tuberculosis or received antituberculosis treatment within 3 months prior to study enrollment; (vii) coinfected with another nontuberculosis mycobacterium; (viii) refused to sign informed consent form; (ix) AIDS. </plain></SENT>
<SENT sid="538" pm="."><plain>In addition, patients with cystic fibrosis were not included in the study; notably, cystic fibrosis is extremely rare among Asian patients. </plain></SENT>
<SENT sid="539" pm="."><plain>A detailed, patient enrollment flow chart is shown in Fig. 2. </plain></SENT>
<SENT sid="540" pm="."><plain>This study was approved by the Ethics Committees of Shanghai Pulmonary Hospital and Tongji University School of Medicine, ethics number K17-150. </plain></SENT>
<SENT sid="541" pm="."><plain>All participants signed informed consent forms before enrollment. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F2" orientation="portrait" position="float"><label>FIG 2</label><caption><p><text><SENT sid="542" pm="."><plain>Flow diagram of the study. </plain></SENT>
<SENT sid="543" pm="."><plain>One hundred M. abscessus lung disease patients who conformed to the inclusion criteria were enrolled. </plain></SENT>
<SENT sid="544" pm="."><plain>Sixty-nine patients were in the CLA-resistant genotype group, including 5 patients infected with rrl 2058-2059 mutants and 64 erm(41)T28-type-infected patients; 31 belonged to the CLA-sensitive group, including 6 erm(41)C28- and 25 erm(41) M-type-infected patients. </plain></SENT>
</text></p></caption><graphic xlink:href="zac0051871220002"/></fig></SecTag></sec><sec id="sec4-2"><title><text><SENT sid="545" pm="."><plain>Collection, identification, and preservation of bacteria. </plain></SENT>
</text></title><p><text><SENT sid="546" pm="."><plain>All the clinical M. abscessus isolates used in this study were preserved in the Clinical Microbiology Laboratory of Shanghai Pulmonary Hospital. </plain></SENT>
<SENT sid="547" pm="."><plain>Shanghai Pulmonary Hospital is one of the designated treatment centers for tuberculosis and NTM disease in China, attracting NTM disease cases nationwide. M. abscessus isolates were obtained from sputum and bronchoalveolar lavage fluid. </plain></SENT>
<SENT sid="548" pm="."><plain>Samples were transferred to Lowenstein-Jensen (L-J) agar plates after treatment with 4% NaOH. </plain></SENT>
<SENT sid="549" pm="."><plain>Smears prepared from the bacterial colonies that grew were stained and examined microscopically to identify the acid-fast organisms. </plain></SENT>
<SENT sid="550" pm="."><plain>To select further NTM, positive colonies were inoculated and cultured in L-J medium containing 0.5 mg/ml P-nitrobenzoic acid and 5 mg/ml 2-thiophenecarboxylic acid hydrazide for 1 to 2 weeks at 37°C. </plain></SENT>
<SENT sid="551" pm="."><plain>Bacterial isolates that grew rapidly were selected for molecular typing by PCR. </plain></SENT>
<SENT sid="552" pm="."><plain>The bacteria were digested with 1 mg/ml lysozyme and 1 mg/ml proteinase K, and the DNA was extracted with phenol-chloroform. </plain></SENT>
<SENT sid="553" pm="."><plain>First, the rpoB gene was amplified by PCR, and the DNA sequences were determined. </plain></SENT>
<SENT sid="554" pm="."><plain>To confirm the M. abscessus complexes, 754 bp of the DNA segment was subjected to BLAST analysis. </plain></SENT>
<SENT sid="555" pm="."><plain>Second, the erm(41) gene was amplified, and the DNA sequence was analyzed to identify and differentiate M. abscessus subsp. massiliense, M. abscessus subsp. abscessus, and M. abscessus subsp. bolletii. </plain></SENT>
<SENT sid="556" pm="."><plain>Finally, the PRA-hsp65 gene was compared to an online reference (<ext-link ext-link-type="uri" xlink:href="http://app.chuv.ch/prasite/index.html">http://app.chuv.ch/prasite/index.html</ext-link>) to confirm the M. abscessus subsp. abscessus and M. abscessus subsp. bolletii identifications. M. abscessus subsp. bolletii was excluded from the study because it is essentially absent in China. </plain></SENT>
<SENT sid="557" pm="."><plain>Identified M. abscessus subsp. abscessus and M. abscessus subsp. massiliense isolates, stored at −80°C, were subsequently recovered for microbiology and molecular biology studies. </plain></SENT>
</text></p></sec><sec id="sec4-3"><title><text><SENT sid="558" pm="."><plain>Identification of colony morphology. </plain></SENT>
</text></title><p><text><SENT sid="559" pm="."><plain>Single colonies were obtained from frozen M. abscessus isolates by growth on Middlebrook 7H10 agar plates supplemented with 10% oleic acid-albumin-dextrose-catalase. </plain></SENT>
<SENT sid="560" pm="."><plain>The colonies were classified macroscopically as smooth or rough. </plain></SENT>
<SENT sid="561" pm="."><plain>If isolates gave rise to colonies of both morphotypes, a colony of each type was analyzed separately, and the identity was established by whole-genome sequencing. </plain></SENT>
</text></p></sec><sec id="sec4-4"><title><text><SENT sid="562" pm="."><plain>Genotype analysis. </plain></SENT>
</text></title><p><text><SENT sid="563" pm="."><plain>Genomic information for all isolates was obtained by whole-genome sequencing. </plain></SENT>
<SENT sid="564" pm="."><plain>Single nucleotide polymorphism (SNP) analysis was performed using the NCBI GenBank database and BLAST algorithm. </plain></SENT>
<SENT sid="565" pm="."><plain>The following genotypes were of specific interest: erm(41) [including erm(41)C28, erm(41)T28, and erm(41) M type], rll wild type, and rrl 2058-2059 mutant. </plain></SENT>
</text></p></sec><sec id="sec4-5"><title><text><SENT sid="566" pm="."><plain>(i) Whole-genome sequencing. </plain></SENT>
</text></title><p><text><SENT sid="567" pm="."><plain>Detailed methods were published previously by us (28). </plain></SENT>
<SENT sid="568" pm="."><plain>DNA was extracted according to the method of Somerville and coworkers (29), and paired-end libraries with insert sizes of ∼400 bp were prepared following Illumina's standard genomic DNA library preparation protocol (Illumina, San Diego, CA, USA). </plain></SENT>
<SENT sid="569" pm="."><plain>After shearing, ligating, and PCR, the qualified Illumina paired-end library was used for Illumina HiSeq sequencing (paired-end 150 bp × 2). </plain></SENT>
<SENT sid="570" pm="."><plain>The default parameters of the SPAdes software (version v.3.6.0) (<ext-link ext-link-type="uri" xlink:href="http://bioinf.spbau.ru/en/spades">http://bioinf.spbau.ru/en/spades</ext-link>) were used to assemble the genome draft (30). </plain></SENT>
<SENT sid="571" pm="."><plain>The assembled product was evaluated using QUAST (version v.2.3) (31; <ext-link ext-link-type="uri" xlink:href="http://quast.bioinf.spbau.ru/">http://quast.bioinf.spbau.ru/</ext-link>). </plain></SENT>
</text></p></sec><sec id="sec4-6"><title><text><SENT sid="572" pm="."><plain>(ii) SNP analysis. </plain></SENT>
</text></title><p><text><SENT sid="573" pm="."><plain>The NCBI Nucleotide BLAST program was used for SNP analysis. </plain></SENT>
<SENT sid="574" pm="."><plain>The standard ATCC 19977 (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/NC_010397.1" assigning-authority="genbank">NC_010397.1</ext-link>) M. abscessus strain served as the reference for rrl and erm(41)T28, CR5701 (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nucleotide/HQ127366.1" assigning-authority="genbank">HQ127366.1</ext-link>) was used as the reference strain for erm(41)C28, and CCUG48898 (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nucleotide/AP014547.1" assigning-authority="genbank">AP014547.1</ext-link>) was the reference for M type. </plain></SENT>
</text></p></sec><sec id="sec4-7"><title><text><SENT sid="575" pm="."><plain>Drug sensitivity assay. </plain></SENT>
</text></title><p><text><SENT sid="576" pm="."><plain>Antibiotic sensitivity was determined by the microdilution method. </plain></SENT>
<SENT sid="577" pm="."><plain>Sulfonamides, moxifloxacin, cefoxitin, amikacin, doxycycline, tigecycline, CLA, linezolid, imipenem, and tobramycin are among the most common antibiotics used to treat M. abscessus infections; each was tested (TREK Diagnostic Systems, Brooklyn Heights, OH, USA). </plain></SENT>
<SENT sid="578" pm="."><plain>CLA resistance was assessed at 3 days and 14 days after M. abscessus exposure. </plain></SENT>
<SENT sid="579" pm="."><plain>Antibiotics' susceptible and resistant breakpoints were interpreted according to Clinical and Laboratory Standards Institute (CLSI) document M24-A2. Staphylococcus aureus (ATCC 29213; American Type Culture Collection, Manassas, VA, USA) served as the control reference strain. </plain></SENT>
</text></p></sec><sec id="sec4-8"><title><text><SENT sid="580" pm="."><plain>Treatment regimen and efficacy evaluation. </plain></SENT>
</text></title><p><text><SENT sid="581" pm="."><plain>All patients were treated with antibiotics as follows: an initial 4-week course of amikacin (15 mg/kg of body weight/day in two equal doses) combined with cefoxitin (200 mg/kg/day with a maximum of 12 g/day in three equal doses) by intravenous administration. </plain></SENT>
<SENT sid="582" pm="."><plain>CLA was also administered orally from the beginning of therapy. </plain></SENT>
<SENT sid="583" pm="."><plain>After 4 weeks, an oral regimen of CLA combined with levofloxacin or moxifloxacin was given. </plain></SENT>
<SENT sid="584" pm="."><plain>If an adverse reaction to either amikacin or cefoxitin occurred, the regimen was replaced with imipenem (500 mg three times a day), linezolid (600 mg once every 12 h), or tigecycline (100 mg initially, followed by 50 mg every 12 h). </plain></SENT>
<SENT sid="585" pm="."><plain>CLA was administered continually throughout the course of treatment as recommended in the guidelines. </plain></SENT>
</text></p><p><text><SENT sid="586" pm="."><plain>All the patients underwent chest CT examination, as well as sputum smears and culture, regularly. </plain></SENT>
<SENT sid="587" pm="."><plain>Therapeutic efficacy was determined according to the results of microbiological examination and radiological changes. </plain></SENT>
<SENT sid="588" pm="."><plain>The clinical characteristics, sputum culture conversion rate and time, radiological improvement rate, and microbiological characteristics of each genotype group were compared. </plain></SENT>
<SENT sid="589" pm="."><plain>Culture conversion was defined as three consecutive negative cultures from sputum specimens. </plain></SENT>
<SENT sid="590" pm="."><plain>Effective treatment was defined as sputum culture negative or significant pulmonary lesion resolution without recurrence during the observation period. </plain></SENT>
<SENT sid="591" pm="."><plain>Ineffective treatment included failure to achieve culture and smear conversion, recurrence after initial culture conversion, and appearance of increased or stable lesions in CT scans. </plain></SENT>
</text></p></sec><sec id="sec4-9"><title><text><SENT sid="592" pm="."><plain>Statistical analysis. </plain></SENT>
</text></title><p><text><SENT sid="593" pm="."><plain>All statistical analyses were conducted using SPSS20.0 (IBM, Armonk, NY, USA). </plain></SENT>
<SENT sid="594" pm="."><plain>The data were compared using Student's t test or the Mann-Whitney U test for continuous variables and the Pearson χ2 test or Fisher exact test for categorical variables. P values of &lt;0.05 were considered statistically significant in a 2-tailed analysis. </plain></SENT>
<SENT sid="595" pm="."><plain>Times to initial culture conversion were compared using the Kaplan-Meier method. </plain></SENT>
<SENT sid="596" pm="."><plain>Potential predictors of the treatment response were assessed by multivariable logistic regression. </plain></SENT>
<SENT sid="597" pm="."><plain>In the logistic regression models, variables with P values of &lt;0.1 in the univariable analysis were included in the multivariable analysis. </plain></SENT>
</text></p></sec><sec id="sec4-10"><title><text><SENT sid="598" pm="."><plain>Accession number(s). </plain></SENT>
</text></title><p><text><SENT sid="599" pm="."><plain>The accession numbers for all the M. abscessus isolates sequenced in this study are available at DDBJ/ENA/GenBank under BioProject <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA398137" assigning-authority="bioproject">PRJNA398137</ext-link>. </plain></SENT>
</text></p></sec></sec></SecTag>
<SecTag type="SUPPL"><sec sec-type="supplementary-material">
<title><text><SENT sid="600" pm="."><plain>Supplementary Material </plain></SENT>
</text></title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title><text><SENT sid="601" pm="."><plain>Supplemental material </plain></SENT>
</text></title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_62_5_e02360-17__index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="AAC.02360-17_zac005187122s1.pdf"/>
</supplementary-material>
</sec></SecTag>
</body><back><fn-group><SecTag type="SUPPL"><fn fn-type="supplementary-material"><p><text><SENT sid="602" pm="."><plain>Supplemental material for this article may be found at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/AAC.02360-17">https://doi.org/10.1128/AAC.02360-17</ext-link>. </plain></SENT>
</text></p></fn></SecTag></fn-group><SecTag type="COMP_INT"><ack><title>ACKNOWLEDGMENTS</title><p>We declare no conflict of interest.</p><p>This project was supported by grants obtained from the National Natural Science Foundation of China (no. 81672063); the Medical Guide Program of Shanghai Science and Technology Committee (no. 14411962900); the Key Project of Shanghai Municipal Health and Family Planning Commission (no. 201540367); the Youth Project of Shanghai Municipal Health and Family Planning Commission (no. 20164Y0230); and the New Frontier Technology Joint Project of Municipal Hospital, Shanghai Shenkang Hospital Development Center (no. SHDC12017113).</p><p>We sincerely thank Stephen H. Gregory (Providence, Rhode Island, USA), who helped write and edit the manuscript.</p></ack></SecTag><SecTag type="REF"><ref-list><title>REFERENCES</title><ref id="B1"><text><SENT sid="603" pm="."><plain>1.PrevotsDR, MarrasTK 2015 Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med 36:13–34. doi:10.1016/j.ccm.2014.10.002.25676516 </plain></SENT>
</text></ref><ref id="B2"><text><SENT sid="604" pm="."><plain>2.HoefslootW, van IngenJ, AndrejakC, AngebyK, BauriaudR, BemerP, BeylisN, BoereeMJ, CachoJ, ChihotaV, ChimaraE, ChurchyardG, CiasR, DazaR, DaleyCL, DekhuijzenPN, DomingoD, DrobniewskiF, EstebanJ, Fauville-DufauxM, FolkvardsenDB, GibbonsN, Gomez-MampasoE, GonzalezR, HoffmannH, HsuehPR, IndraA, JagielskiT, JamiesonF, JankovicM, JongE, KeaneJ, KohWJ, LangeB, LeaoS, MacedoR, MannsakerT, MarrasTK, MaugeinJ, MilburnHJ, MlinkoT, MorcilloN, MorimotoK, PapaventsisD, PalenqueE, Paez-PenaM, PiersimoniC, PolanovaM, RastogiN, RichterE, Ruiz-SerranoMJ, SilvaA, da SilvaMP, SimsekH, van SoolingenD, SzabóN, ThomsonR, Tórtola FernandezT, TortoliE, TottenSE, TyrrellG, VasankariT, VillarM, WalkiewiczR, WinthropKL, WagnerD, Nontuberculous Mycobacteria Network European Trials Group. 2013 The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J 42:1604–1613. doi:10.1183/09031936.00149212.23598956 </plain></SENT>
</text></ref><ref id="B3"><text><SENT sid="605" pm="."><plain>3.BrodeSK, DaleyCL, MarrasTK 2014 The epidemiologic relationship between tuberculosis and non-tuberculous mycobacterial disease: a systematic review. Int J Tuberc Lung Dis 18:1370–1377. doi:10.5588/ijtld.14.0120.25299873 </plain></SENT>
</text></ref><ref id="B4"><text><SENT sid="606" pm="."><plain>4.GuimaraesT, ChimaraE, do PradoGV, FerrazoliL, CarvalhoNG, SimeaoFC, de SouzaAR, CostaCA, Viana NieroC, BrianesiUA, di GioiaTR, GomesLM, SpadaoFS, SilvaMD, de MouraEG, LevinAS 2016 Pseudooutbreak of rapidly growing mycobacteria due to Mycobacterium abscessus subsp. bolletii in a digestive and respiratory endoscopy unit caused by the same clone as that of a countrywide outbreak. Am J Infect Control 44:e221–e226. doi:10.1016/j.ajic.2016.06.019.27524260 </plain></SENT>
</text></ref><ref id="B5"><text><SENT sid="607" pm="."><plain>5.BryantJM, GrogonoDM, Rodriguez-RinconD, EverallI, BrownKP, MorenoP, VermaD, HillE, DrijkoningenJ, GilliganP, EstherCR, NoonePG, GiddingsO, BellSC, ThomsonR, WainwrightCE, CoulterC, PandeyS, WoodME, StockwellRE, RamsayKA, SherrardLJ, KiddTJ, JabbourN, JohnsonGR, KnibbsLD, MorawskaL, SlyPD, JonesA, BiltonD, LaurensonI, RuddyM, BourkeS, BowlerIC, ChapmanSJ, ClaytonA, CullenM, DempseyO, DentonM, DesaiM, DrewRJ, EdenboroughF, EvansJ, FolbJ, DanielsT, HumphreyH, IsalskaB, Jensen-FangelS, JonssonB, JonesAM, KatzensteinTL, LillebaekT, MacGregorG, MayellS, MillarM, ModhaD, NashEF, O'BrienC, O'BrienD, OhriC, PaoCS, PeckhamD, PerrinF, PerryA, PresslerT, PrtakL, QvistT, RobbA, RodgersH, SchafferK, ShafiN, van IngenJ, WalshawM, WatsonD, WestN, WhitehouseJ, HaworthCS, HarrisSR, OrdwayD, ParkhillJ, FlotoRA 2016 Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science 354:751–757. doi:10.1126/science.aaf8156.27846606 </plain></SENT>
</text></ref><ref id="B6"><text><SENT sid="608" pm="."><plain>6.FlotoRA, OlivierKN, SaimanL, DaleyCL, HerrmannJL, NickJA, NoonePG, BiltonD, CorrisP, GibsonRL, HempsteadSE, KoetzK, SabadosaKA, Sermet-GaudelusI, SmythAR, van IngenJ, WallaceRJ, WinthropKL, MarshallBC, HaworthCS 2016 US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary. Thorax 71:88–90. doi:10.1136/thoraxjnl-2015-207983.26678435 </plain></SENT>
</text></ref><ref id="B7"><text><SENT sid="609" pm="."><plain>7.FlotoRA, OlivierKN, SaimanL, DaleyCL, HerrmannJL, NickJA, NoonePG, BiltonD, CorrisP, GibsonRL, HempsteadSE, KoetzK, SabadosaKA, Sermet-GaudelusI, SmythAR, van IngenJ, WallaceRJ, WinthropKL, MarshallBC, HaworthCS, US Cystic Fibrosis Foundation, European Cystic Fibrosis Society. 2016 US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax 71(Suppl 1):i1–22. doi:10.1136/thoraxjnl-2015-207360.26666259 </plain></SENT>
</text></ref><ref id="B8"><text><SENT sid="610" pm="."><plain>8.GriffithDE, AksamitT, Brown-ElliottBA, CatanzaroA, DaleyC, GordinF, HollandSM, HorsburghR, HuittG, IademarcoMF, IsemanM, OlivierK, RuossS, von ReynCF, WallaceRJJr, WinthropK, ATS Mycobacterial Diseases Subcommittee, American Thoracic Society, Infectious Disease Society of America. 2007 An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175:367–416. doi:10.1164/rccm.200604-571ST.17277290 </plain></SENT>
</text></ref><ref id="B9"><text><SENT sid="611" pm="."><plain>9.GriffithDE, GirardWM, WallaceRJJr 1993 Clinical features of pulmonary disease caused by rapidly growing mycobacteria. </plain></SENT>
<SENT sid="612" pm="."><plain>An analysis of 154 patients. Am Rev Respir Dis 147:1271–1278. doi:10.1164/ajrccm/147.5.1271.8484642 </plain></SENT>
</text></ref><ref id="B10"><text><SENT sid="613" pm="."><plain>10.LaiCC, TanCK, ChouCH, HsuHL, LiaoCH, HuangYT, YangPC, LuhKT, HsuehPR 2010 Increasing incidence of nontuberculous mycobacteria, Taiwan, 2000-2008. Emerg Infect Dis 16:294–296. doi:10.3201/eid1602.090675.20113563 </plain></SENT>
</text></ref><ref id="B11"><text><SENT sid="614" pm="."><plain>11.MarrasTK, MendelsonD, Marchand-AustinA, MayK, JamiesonFB 2013 Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998-2010. Emerg Infect Dis 19:1889–1891. doi:10.3201/eid1911.130737.24210012 </plain></SENT>
</text></ref><ref id="B12"><text><SENT sid="615" pm="."><plain>12.NessarR, CambauE, ReyratJM, MurrayA, GicquelB 2012 Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother 67:810–818. doi:10.1093/jac/dkr578.22290346 </plain></SENT>
</text></ref><ref id="B13"><text><SENT sid="616" pm="."><plain>13.WallaceRJJr, MeierA, BrownBA, ZhangY, SanderP, OnyiGO, BottgerEC 1996 Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother 40:1676–1681.8807061 </plain></SENT>
</text></ref><ref id="B14"><text><SENT sid="617" pm="."><plain>14.NashKA, Brown-ElliottBA, WallaceRJJr 2009 A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 53:1367–1376. doi:10.1128/AAC.01275-08.19171799 </plain></SENT>
</text></ref><ref id="B15"><text><SENT sid="618" pm="."><plain>15.BastianS, VezirisN, RouxAL, BrossierF, GaillardJL, JarlierV, CambauE 2011 Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother 55:775–781. doi:10.1128/AAC.00861-10.21135185 </plain></SENT>
</text></ref><ref id="B16"><text><SENT sid="619" pm="."><plain>16.RubioM, MarchF, GarrigoM, MorenoC, EspanolM, CollP 2015 Inducible and acquired clarithromycin resistance in the Mycobacterium abscessus complex. PLoS One 10:e0140166. doi:10.1371/journal.pone.0140166.26448181 </plain></SENT>
</text></ref><ref id="B17"><text><SENT sid="620" pm="."><plain>17.HaradaT, AkiyamaY, KurashimaA, NagaiH, TsuyuguchiK, FujiiT, YanoS, ShigetoE, KuraokaT, KajikiA, KobashiY, KokubuF, SatoA, YoshidaS, IwamotoT, SaitoH 2012 Clinical and microbiological differences between Mycobacterium abscessus and Mycobacterium massiliense lung diseases. J Clin Microbiol 50:3556–3561. doi:10.1128/JCM.01175-12.22915613 </plain></SENT>
</text></ref><ref id="B18"><text><SENT sid="621" pm="."><plain>18.KohWJ, JeonK, LeeNY, KimBJ, KookYH, LeeSH, ParkYK, KimCK, ShinSJ, HuittGA, DaleyCL, KwonOJ 2011 Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 183:405–410. doi:10.1164/rccm.201003-0395OC.20833823 </plain></SENT>
</text></ref><ref id="B19"><text><SENT sid="622" pm="."><plain>19.KohWJ, JeongBH, KimSY, JeonK, ParkKU, JhunBW, LeeH, ParkHY, KimDH, HuhHJ, KiCS, LeeNY, KimHK, ChoiYS, KimJ, LeeSH, KimCK, ShinSJ, DaleyCL, KimH, KwonOJ 2017 Mycobacterial characteristics and treatment outcomes in Mycobacterium abscessus lung disease. Clin Infect Dis 64:309–316. doi:10.1093/cid/ciw724.28011608 </plain></SENT>
</text></ref><ref id="B20"><text><SENT sid="623" pm="."><plain>20.ParkJ, ChoJ, LeeCH, HanSK, YimJJ 2017 Progression and treatment outcomes of lung disease caused by Mycobacterium abscessus and Mycobacterium massiliense. Clin Infect Dis 64:301–308. doi:10.1093/cid/ciw723.28011609 </plain></SENT>
</text></ref><ref id="B21"><text><SENT sid="624" pm="."><plain>21.KimHY, KimBJ, KookY, YunYJ, ShinJH, KimBJ, KookYH 2010 Mycobacterium massiliense is differentiated from Mycobacterium abscessus and Mycobacterium bolletii by erythromycin ribosome methyltransferase gene (erm) and clarithromycin susceptibility patterns. Microbiol Immunol 54:347–353. doi:10.1111/j.1348-0421.2010.00221.x.20536733 </plain></SENT>
</text></ref><ref id="B22"><text><SENT sid="625" pm="."><plain>22.MougariF, AmarsyR, VezirisN, BastianS, BrossierF, BercotB, RaskineL, CambauE 2016 Standardized interpretation of antibiotic susceptibility testing and resistance genotyping for Mycobacterium abscessus with regard to subspecies and erm41 sequevar. J Antimicrob Chemother 71:2208–2212. doi:10.1093/jac/dkw130.27147307 </plain></SENT>
</text></ref><ref id="B23"><text><SENT sid="626" pm="."><plain>23.MougariF, BouzianeF, CrockettF, NessarR, ChauF, VezirisN, SaprielG, RaskineL, CambauE 2017 Selection of resistance to clarithromycin in Mycobacterium abscessus subspecies. Antimicrob Agents Chemother 61:e00943-16. doi:10.1128/AAC.00943-16.27799212 </plain></SENT>
</text></ref><ref id="B24"><text><SENT sid="627" pm="."><plain>24.AdekambiT, BergerP, RaoultD, DrancourtM 2006 rpoB gene sequence-based characterization of emerging non-tuberculous mycobacteria with descriptions of Mycobacterium bolletii sp. nov., Mycobacterium phocaicum sp. nov. and Mycobacterium aubagnense sp. nov. Int J Syst Evol Microbiol 56:133–143. doi:10.1099/ijs.0.63969-0.16403878 </plain></SENT>
</text></ref><ref id="B25"><text><SENT sid="628" pm="."><plain>25.BonaitiG, PesciA, MarruchellaA, LapadulaG, GoriA, AlibertiS 2015 Nontuberculous mycobacteria in noncystic fibrosis bronchiectasis. Biomed Res Int 2015:197950. doi:10.1155/2015/197950.26106603 </plain></SENT>
</text></ref><ref id="B26"><text><SENT sid="629" pm="."><plain>26.LeeMR, YangCY, ChangKP, KengLT, YenDH, WangJY, WuHD, LeeLN, YuCJ 2013 Factors associated with lung function decline in patients with non-tuberculous mycobacterial pulmonary disease. PLoS One 8:e58214. doi:10.1371/journal.pone.0058214.23483998 </plain></SENT>
</text></ref><ref id="B27"><text><SENT sid="630" pm="."><plain>27.JonssonBE, GilljamM, LindbladA, RidellM, WoldAE, Welinder-OlssonC 2007 Molecular epidemiology of Mycobacterium abscessus, with focus on cystic fibrosis. J Clin Microbiol 45:1497–1504. doi:10.1128/JCM.02592-06.17376883 </plain></SENT>
</text></ref><ref id="B28"><text><SENT sid="631" pm="."><plain>28.LuoL, LiuW, LiB, LiM, HuangD, JingL, ChenH, YangJ, YueJ, WangF, ChuH, ZhangZ 2016 Evaluation of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of Mycobacterium abscessus subspecies according to whole-genome sequencing. J Clin Microbiol 54:2982–2989. doi:10.1128/JCM.01151-16.27682129 </plain></SENT>
</text></ref><ref id="B29"><text><SENT sid="632" pm="."><plain>29.SomervilleW, ThibertL, SchwartzmanK, BehrMA 2005 Extraction of Mycobacterium tuberculosis DNA: a question of containment. J Clin Microbiol 43:2996–2997. doi:10.1128/JCM.43.6.2996-2997.2005.15956443 </plain></SENT>
</text></ref><ref id="B30"><text><SENT sid="633" pm="."><plain>30.BankevichA, NurkS, AntipovD, GurevichAA, DvorkinM, KulikovAS, LesinVM, NikolenkoSI, PhamS, PrjibelskiAD, PyshkinAV, SirotkinAV, VyahhiN, TeslerG, AlekseyevMA, PevznerPA 2012 SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol 19:455–477. doi:10.1089/cmb.2012.0021.22506599 </plain></SENT>
</text></ref><ref id="B31"><text><SENT sid="634" pm="."><plain>31.GurevichA, SavelievV, VyahhiN, TeslerG 2013 QUAST: quality assessment tool for genome assemblies. Bioinformatics 29:1072–1075. doi:10.1093/bioinformatics/btt086.23422339 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
